CO7 Patient reported outcome measure for giant cell arteritis: cross-sectional validation study
(2022)
Presentation / Conference Contribution
Outputs (6)
POS0003 Development and validation of a disease specific patient reported outcome for giant cell arteritis (2022)
Presentation / Conference Contribution
Background
Giant cell arteritis (GCA) is caused by inflammation of the blood vessels of the head and neck; patients can present with cranial, ocular or large vessel vasculitis involvement. Treatment is with glucocorticoids, steroid sparing agents a... Read More about POS0003 Development and validation of a disease specific patient reported outcome for giant cell arteritis.
P301 Patient reported outcome measure for giant cell arteritis: Clinical testing (2022)
Presentation / Conference Contribution
Background/Aims
Giant cell arteritis (GCA) presents in people over 50, with headaches, visual involvement and large vessel vasculitis. A 30-item GCA-specific patient reported outcome measure (GCA PRO) was developed and tested in a clinical setting t... Read More about P301 Patient reported outcome measure for giant cell arteritis: Clinical testing.
OA23 Patient-reported outcome measure for giant cell arteritis: Cross-sectional validation study (2022)
Presentation / Conference Contribution
Development and validation of a patient reported outcome measure for giant cell arteritis (2021)
Presentation / Conference Contribution
Patient perceptions of health-related quality of life in giant cell arteritis: International development of a disease-specific patient-reported outcome measure (2021)
Journal Article
Objectives: GCA is a large vessel vasculitis (LVV) presenting with headache, jaw claudication, musculoskeletal and visual involvement. Current treatment is glucocorticoids and anti-IL-6 tocilizumab in refractory disease. The objective of this study w... Read More about Patient perceptions of health-related quality of life in giant cell arteritis: International development of a disease-specific patient-reported outcome measure.